HER2-negative Breast Cancer Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Daiichi Sankyo, Inc., Eisai Inc., AstraZeneca

Posted on
by

HER2-negative Breast Cancer Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Daiichi Sankyo, Inc., Eisai Inc., AstraZeneca
DelveInsight’s “HER2-negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the HER2-negative Breast Cancer.

DelveInsight’s “HER2-negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the HER2-negative Breast Cancer, historical and forecasted epidemiology as well as the HER2-negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the HER2-negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-negative Breast Cancer Market Forecast

 

Some of the key facts of the HER2-negative Breast Cancer Market Report: 

  • The HER2-negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the Global Cancer Observatory (2020), there were 253,465 new breast cancer cases in the United States in 2020
  • As per the Breast Cancer Facts and Figures (2019–2020) by the American Cancer Society, at the time of diagnosis, approximately 64% of breast cancer patients have local-stage breast cancer, 27% have the regional stage, and 6% have the distant (metastatic) disease
  • According to the Global Cancer Observatory (2020), the number of new breast cancer cases in Germany, France, Italy, Spain, the United Kingdom were 69,697, 58,083, 55,133, 34,088, and 53,889, respectively, in 2020
  • Of the HER2-negative Breast Cancer emerging therapies, one of the most anticipated products to get launched is sacituzumab govitecan (already approved in the US for triple-negaƟve breast cancer; for HR+ HER2− Breast cancer, Phase III clinical study is ongoing). Apart from this, several other molecules are in the late stage, such as inavolisib, RG6171/ GDC-9545, and elacestrant/RAD1901, and others
  • Key HER2-negative Breast Cancer Companies: Daiichi Sankyo, Inc., Eisai Inc., AstraZeneca, Adagene Inc, Novartis, Genentech, Inc., Gilead, Hoffmann-La Roche, Olema Pharma, SCRI Development Innovations, Radius Pharmaceuticals, Quotient Sciences, Merrimack Pharmaceuticals, BeiGene, and others
  • Key HER2-negative Breast Cancer Therapies: Doxorubicin, Fulvestrant, MM-121, BGB-290, AZD9833, [14C]AZD9833, OP-1250, Eribulin, Cyclophosphamide, ADG106, Capecitabine, Trodelvy (Sacituzumab Govitecanhziy/GS-0132), RG6171, GDC-9545, RAD1901, Inavolisib(RG6114, GDC-0077), and others
  • The HER2-negative Breast Cancer epidemiology base on gender analyze that HER2-negative breast cancer mainly develops in older women
  • The HER2-negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-negative Breast Cancer pipeline products will significantly revolutionize the HER2-negative Breast Cancer market dynamics.

 

HER2-negative Breast Cancer Overview

Breast cancer initiates when abnormal cancerous cells in the breast grow and multiply without stopping, creating a tumor. It usually starts in the ducts or lobules of the breast. Cancer cells get many signals that drive their growth. These signals may take the form of hormones.

 

Get a Free sample for the HER2-negative Breast Cancer Market Report 

https://www.delveinsight.com/report-store/her2-negative-breast-cancer-market

 

HER2-negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

HER2-negative Breast Cancer Epidemiology Segmentation:

The HER2-negative Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of HER2-negative Breast Cancer
  • Prevalent Cases of HER2-negative Breast Cancer by severity
  • Gender-specific Prevalence of HER2-negative Breast Cancer
  • Diagnosed Cases of Episodic and Chronic HER2-negative Breast Cancer

 

Download the report to understand which factors are driving HER2-negative Breast Cancer epidemiology trends @ HER2-negative Breast Cancer Epidemiology Forecast

 

HER2-negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-negative Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the HER2-negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

HER2-negative Breast Cancer Therapies and Key Companies

  • Trodelvy (Sacituzumab Govitecanhziy/GS-0132): Gilead
  • RG6171/ GDC-9545: Hoffmann-La Roche
  • RAD1901: Radius Pharmaceuticals
  • Inavolisib(RG6114, GDC-0077): Hoffmann-La Roche
  • Doxorubicin: Genentech, Inc.
  • Fulvestrant: Novartis
  • MM-121: Merrimack Pharmaceuticals
  • BGB-290: BeiGene
  • AZD9833: AstraZeneca
  • [14C]AZD9833: Quotient Sciences
  • OP-1250: Olema Pharma
  • Eribulin: SCRI Development Innovations
  • Cyclophosphamide: Eisai Inc.
  • ADG106: Adagene Inc
  • Capecitabine: Daiichi Sankyo, Inc.

 

Discover more about therapies set to grab major HER2-negative Breast Cancer market share @ HER2-negative Breast Cancer Treatment Market

 

Scope of the HER2-negative Breast Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key HER2-negative Breast Cancer Companies: Daiichi Sankyo, Inc., Eisai Inc., AstraZeneca, Adagene Inc, Novartis, Genentech, Inc., Gilead, Hoffmann-La Roche, Olema Pharma, SCRI Development Innovations, Radius Pharmaceuticals, Quotient Sciences, Merrimack Pharmaceuticals, BeiGene, and others
  • Key HER2-negative Breast Cancer Therapies: Doxorubicin, Fulvestrant, MM-121, BGB-290, AZD9833, [14C]AZD9833, OP-1250, Eribulin, Cyclophosphamide, ADG106, Capecitabine, Trodelvy (Sacituzumab Govitecanhziy/GS-0132), RG6171, GDC-9545, RAD1901, Inavolisib(RG6114, GDC-0077), and others
  • HER2-negative Breast Cancer Therapeutic Assessment: HER2-negative Breast Cancer current marketed and HER2-negative Breast Cancer emerging therapies
  • HER2-negative Breast Cancer Market Dynamics: HER2-negative Breast Cancer market drivers and HER2-negative Breast Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • HER2-negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2-negative Breast Cancer Market Access and Reimbursement 

 

To know more about HER2-negative Breast Cancer companies working in the treatment market, visit @ HER2-negative Breast Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. HER2-negative Breast Cancer Market Report Introduction

2. Executive Summary for HER2-negative Breast Cancer

3. SWOT analysis of HER2-negative Breast Cancer

4. HER2-negative Breast Cancer Patient Share (%) Overview at a Glance

5. HER2-negative Breast Cancer Market Overview at a Glance

6. HER2-negative Breast Cancer Disease Background and Overview

7. HER2-negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2-negative Breast Cancer 

9. HER2-negative Breast Cancer Current Treatment and Medical Practices

10. HER2-negative Breast Cancer Unmet Needs

11. HER2-negative Breast Cancer Emerging Therapies

12. HER2-negative Breast Cancer Market Outlook

13. Country-Wise HER2-negative Breast Cancer Market Analysis (2019–2032)

14. HER2-negative Breast Cancer Market Access and Reimbursement of Therapies

15. HER2-negative Breast Cancer Market Drivers

16. HER2-negative Breast Cancer Market Barriers

17.  HER2-negative Breast Cancer Appendix

18. HER2-negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services